What is PolyPid?
PolyPid Ltd. is a biopharmaceutical firm dedicated to improving surgical results by developing and administering localized, extended-release therapeutics. The company leverages its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which integrates with Active Pharmaceutical Ingredients (APIs) to ensure precise drug delivery at optimal rates over extended periods, from days to months. PolyPid's lead product candidate, D-PLEX100, is currently undergoing Phase 3 clinical trials for the prevention of surgical site infections in abdominal and sternal bone procedures. Furthermore, the company is exploring the potential of OncoPLEX in preclinical stages for the treatment of solid tumors, with an initial focus on glioblastoma.
How much funding has PolyPid raised?
PolyPid has raised a total of $139.9M across 8 funding rounds:
Series A
$2.2M
Series B
$10.9M
Series C
$8.3M
Series D
$22M
Private Equity
$5.3M
Series E
$50M
Debt
$14.5M
Stock/Share Issuance
$26.7M
Series A (2011): $2.2M, investors not publicly disclosed
Series B (2014): $10.9M, investors not publicly disclosed
Series C (2015): $8.3M supported by GUIBOR and Financiere Saint James
Series D (2016): $22M featuring Shavit Capital and Aurum Ventures Private
Private Equity (2016): $5.3M backed by Xenia Venture Capital
Series E (2019): $50M with participation from Undisclosed
Debt (2024): $14.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $26.7M, investors not publicly disclosed
Key Investors in PolyPid
Shavit Capital
Shavit Capital is a private equity firm specializing in late-stage investments in Israeli and Israeli-related companies, focusing on equity mezzanine or bridge rounds for companies anticipating an IPO on major international public exchanges.
Aurum Ventures Private
Aurum Ventures is a specialized real estate investment and asset management company headquartered in Mumbai, India, focusing on developing, operating, and owning high-quality real estate assets through its in-house teams.
Xenia Venture Capital
Xenia Venture Capital is a publicly traded hi-tech investment company on the Tel Aviv Stock Exchange, primarily focused on investing in high tech and med tech sectors in Israel, and operates a technological incubator.
What's next for PolyPid?
The recent major enterprise-level funding and strategic investment signal a pivotal phase for PolyPid. This capital infusion is expected to accelerate the advancement of D-PLEX100 through its Phase 3 trials and support the preclinical development of OncoPLEX. The company's focus on addressing critical unmet needs in surgical site infection prevention and oncology treatment positions it for significant growth. Future strategic initiatives will likely involve further clinical development, regulatory submissions, and potential commercialization partnerships, leveraging its PLEX technology platform to create a pipeline of innovative therapeutic solutions.
See full PolyPid company page
